Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.74 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | USP1 | O94782 | 2/20 | 0.51 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24803252 | 0.87 | APP (0.57) | APPCCNE2CCNE1CDK2MEN1 | |
| SCHEMBL5107781 | 0.86 | APP (0.71) | APPCCNE2CCNE1CDK2MEN1 | |
| SCHEMBL4859931 | 0.85 | APP (0.70) | APPCCNE2CCNE1CDK2MEN1 | |
| SCHEMBL4866870 | 0.84 | APP (0.73) | APPCCNE2CCNE1CDK2MEN1 | |
| SCHEMBL4864021 | 0.84 | APP (0.73) | APPCCNE2CCNE1CDK2MEN1 | |
| SCHEMBL4863396 | 0.84 | APP (0.73) | APPCCNE2CCNE1CDK2MEN1 | |
| SCHEMBL4868511 | 0.83 | APP (0.67) | APPCCNE2CCNE1CDK2MEN1 | |
| SCHEMBL26069922 | 0.83 | SOS1 (0.63) | APPMEN1KMT2AMITFLMNA | |
| SCHEMBL3977315 | 0.83 | RAD52 (0.71) | APPMEN1KMT2ABCHEACHE | |
| SCHEMBL25112495 | 0.82 | APP (0.52) | APPMITFLMNAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | APP 4386/4885CCNE2 3496/4885CCNE1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.